← Back to Search

SGLT2 Inhibitor

SGLT2 Inhibitor for Kidney Transplant Recipients with Diabetes (INFINITI2019 Trial)

Phase 3

Recruiting

Led By Sunita KS Singh, MD MSc FRCPC

Research Sponsored by University Health Network, Toronto

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

In patients with T2D or PTDM, HbA1c <12.0%

Male or females >18 years old ≥ 6months after kidney transplantation

Must not have

Diagnosis of type 1 diabetes

Patients currently using antipsychotic medications

Timeline

Screening 3 weeks

Treatment Varies

Follow Up change from baseline proximal tubular natriuresis at 12 weeks of treatment

Awards & highlights

Pivotal Trial

Summary

This trial will compare the SGLT2 inhibitor dapagliflozin to placebo in 52 kidney transplant recipients with diabetes. The primary outcome is to determine if dapagliflozin is superior to placebo in reduction of blood pressure in KTR.

Who is the study for?

This trial is for kidney transplant recipients over 18, with or without type 2 diabetes, who are at least six months post-transplant. They should have a stable graft function (eGFR ≥30), controlled blood pressure and HbA1c <12.0%. Exclusions include severe vascular disease, recent acute rejection or cardiovascular events, use of SGLT2 inhibitors within the last month, untreated infections, and certain medication uses.

What is being tested?

The study tests if Dapagliflozin can better reduce blood pressure compared to a placebo in kidney transplant recipients. It's randomized and double-blind meaning neither participants nor researchers know who gets the real drug versus placebo during the trial.

What are the potential side effects?

Potential side effects of Dapagliflozin may include yeast infections due to sugar in urine, urination issues, dehydration risks leading to low blood pressure, possible kidney harm or increased cholesterol levels.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My HbA1c level is below 12.0%.

Select...

I am over 18 and had a kidney transplant more than 6 months ago.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I have been diagnosed with type 1 diabetes.

Select...

I am currently taking antipsychotic medications.

Select...

I have severe issues with my blood vessels, like amputation or non-healing wounds.

Select...

I haven't started or stopped any immune-weakening drugs in the last month.

Select...

I currently have an untreated infection in my urinary or genital area.

Select...

I am a pre-menopausal woman not using birth control and am pregnant, nursing, or could become pregnant.

Select...

I have had a severe low blood sugar episode or didn't notice my low blood sugar levels in the last 3 months.

Select...

I have not taken SGLT2 inhibitors in the last month.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ change from baseline tubulointerstitial hypoxia at 12 weeks of treatment

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~change from baseline tubulointerstitial hypoxia at 12 weeks of treatment

This trial's timeline: 3 weeks for screening, Varies for treatment, and change from baseline tubulointerstitial hypoxia at 12 weeks of treatment for reporting.